AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15830236 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 22
Study 15830236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15830236 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness condition
Number of subjects: 22
Study 15830236 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem and Triazolam
Number of subjects: 22
Study 11840184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamarind (10 g daily for 18 days)
Number of subjects: 20
Study 11840184 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study 10231256 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma resource centre intervention with nurse specialists educating practice nurses and patients.
Number of subjects: 1621
Study 10231256 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma resource centre intervention.
Number of subjects: 1621
Study 9101833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolization (TA)
Number of subjects: 39
Study 9101833 — intervention group
Group type: COMPARATOR
Intervention: Liver resection
Number of subjects: 39
Study 1852516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral albuterol (0.15 mg/kg/dose q8h)
Number of subjects: 30
Study 1852516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D5/W)
Number of subjects: 30
Study 6365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg every 12 h)
Number of subjects: 30
Study 6365701 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (1,000 mg initially, then 500 mg every 12 h)
Number of subjects: 30
Study 6365701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic treatment of missing teeth
Number of subjects: 387
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of caries
Number of subjects: 387
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of oral mucosal diseases
Number of subjects: 387
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional periodontal treatment
Number of subjects: 387
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of oral hygiene
Number of subjects: 387
Study 30951624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncological treatment of pre-cancerous and cancerous lesions
Number of subjects: 387
Study 28970213 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 336
Study 28970213 — intervention group
Group type: COMPARATOR
Intervention: Control (DESIR cohort)
Number of subjects: 336
Study 27064606 — intervention group
Group type: EXPERIMENTAL
Intervention: PLST-based intervention
Number of subjects: 65
Study 27064606 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 65
Study 25385320 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenously prepared DFDBA from Tata Memorial Hospital (TMH) Tissue Bank
Number of subjects: 16
Study 25385320 — intervention group
Group type: COMPARATOR
Intervention: DFDBA from Pacific Coast Tissue Bank (DEMBONE)
Number of subjects: 16
Study 22747420 — intervention group
Group type: EXPERIMENTAL
Intervention: efonidipine
Number of subjects: 14
Study 22747420 — intervention group
Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 14
Study 22747420 — intervention group
Group type: COMPARATOR
Intervention: amiodipine
Number of subjects: 14
Study 20025832 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dieting group interventions (10-week duration)
Number of subjects: 119
Study 19138914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric airway exchange catheter (PAEC) in Group M (MIAS position)
Number of subjects: 100
Study 19138914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric airway exchange catheter (PAEC) in Group S (sniffing position)
Number of subjects: 100
Study 15790202 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (PPH)
Number of subjects: 40
Study 15790202 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan haemorrhoidectomy (MM)
Number of subjects: 40
Study 15790202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 12094707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Number of subjects: 243
Study 12094707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernitin pollen extract
Number of subjects: 243
Study 12094707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin hydrochloride and cernitin pollen extract
Number of subjects: 243
Study 10604884 — intervention group
Group type: COMPARATOR
Intervention: stent-placebo
Number of subjects: 491
Study 10604884 — intervention group
Group type: COMPARATOR
Intervention: balloon-abciximab
Number of subjects: 491
Study 10604884 — intervention group
Group type: EXPERIMENTAL
Intervention: stent-abciximab
Number of subjects: 491
Study 8862090 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF at 125 micrograms/m2/day
Number of subjects: 23
Study 8862090 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF at 250 micrograms/m2/day
Number of subjects: 23
Study 8862090 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 1805808 — intervention group
Group type: EXPERIMENTAL
Intervention: RoC 15+ A+B
Number of subjects: 0
Study 1805808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun E45 lotion SPF 15
Number of subjects: 0
Study 1805808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun E45 cream SPF 25
Number of subjects: 0
Study 6132229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilised human diploid-cell-strain rabies vaccine
Number of subjects: 0
Study 6132229 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Number of subjects: 0
Study 31047857 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (physical training, cognitive training, nutritional counseling, cardiovascular monitoring) for 2 years
Number of subjects: 0
Study 31047857 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (cognitive training, physical activity counseling, nutritional counseling) with omega-3 supplement for 3 years
Number of subjects: 0
Study 31047857 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised computer-based cognitive training
Number of subjects: 0
Study 31047857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28992918 — intervention group
Group type: EXPERIMENTAL
Intervention: wildlife protection frame
Number of subjects: 512
Study 28992918 — intervention group
Group type: EXPERIMENTAL
Intervention: cat benefit frame
Number of subjects: 512
Study 28992918 — intervention group
Group type: COMPARATOR
Intervention: neutral frame
Number of subjects: 512
Study 26803476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Chemohyperthermia (CHT) with Mitomycin C (MMC)
Number of subjects: 190
Study 26803476 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 190
Study 24719123 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot drug-eluting stent (DES) implantation
Number of subjects: 1619
Study 24719123 — intervention group
Group type: COMPARATOR
Intervention: Full lesion coverage
Number of subjects: 1619
Study 22266897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release (150, 300, 450, or 600 mg)
Number of subjects: 138
Study 22266897 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl 150 mg with epinephrine
Number of subjects: 138
Study 22266897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release
Number of subjects: 138
Study 19329467 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG guidance (n=121)
Number of subjects: 249
Study 19329467 — intervention group
Group type: COMPARATOR
Intervention: Landmark guidance (n=128)
Number of subjects: 249
Study 16816963 — intervention group
Group type: EXPERIMENTAL
Intervention: ICARE lens
Number of subjects: 40
Study 16816963 — intervention group
Group type: COMPARATOR
Intervention: Verisyse lens
Number of subjects: 40
Study 17326351 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-LASIK (Moria Epi-K)
Number of subjects: 20
Study 17326351 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 20
Study 15020522 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary bypass surgery
Number of subjects: 281
Study 15020522 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary bypass surgery
Number of subjects: 281
Study 10770311 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline targeting Wolbachia spp bacteria
Number of subjects: 0
Study 9342068 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 4 mg/kg daily for 3 weeks followed by fluconazole 400 mg daily for 7 weeks
Number of subjects: 28
Study 9342068 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.7 mg/kg daily for 3 weeks followed by fluconazole 400 mg daily for 7 weeks
Number of subjects: 28
Study 9342068 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 28
Study 8450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant triazolam infusion (mean concentration 2.48 ng/ml for 9 h)
Number of subjects: 10
Study 8450449 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-infusion treatment
Number of subjects: 10
Study 8450449 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 3620274 — intervention group
Group type: EXPERIMENTAL
Intervention: isoxicam (maximum = 200 mg day‐1)
Number of subjects: 57
Study 3620274 — intervention group
Group type: COMPARATOR
Intervention: piroxicam (maximum = 20 mg day‐1)
Number of subjects: 57
Study 30692242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop with diluted insulin (U20)
Number of subjects: 24
Study 30692242 — intervention group
Group type: COMPARATOR
Intervention: Hybrid closed-loop with standard strength insulin (U100)
Number of subjects: 24
Study 27386745 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (56-84 g/day) for 12 weeks
Number of subjects: 61
Study 27386745 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet without peanuts for 12 weeks
Number of subjects: 61
Study 25499006 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb (diasiirin cross-linked hemoglobin) as add-on therapy
Number of subjects: 98
Study 25499006 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 98
Study 23453111 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 300 μg daily subcutaneous injection for 5 days
Number of subjects: 100
Study 23453111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 22164957 — intervention group
Group type: COMPARATOR
Intervention: Dietary CLA 0%
Number of subjects: 384
Study 22164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CLA 1%
Number of subjects: 384
Study 22164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CLA 2%
Number of subjects: 384
Study 22164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CLA 4%
Number of subjects: 384
Study 22164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CLA (0%, 1%, 2%, 4%)
Number of subjects: 384
Study 22164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary CLA (1%, 2%)
Number of subjects: 384
Study 19930850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 20
Study 19930850 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 20
Study 19930850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 16917926 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein+Carbohydrate (PC)
Number of subjects: 26
Study 16917926 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric‐Carbohydrate (IC)
Number of subjects: 26
Study 16917926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 15319458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal tracheal occlusion (TO)
Number of subjects: 20
Study 15319458 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 20
Study 11450358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and biochemical analysis after 3 weeks of controlled abstinence
Number of subjects: 30
Study 11450358 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography and biochemical analysis
Number of subjects: 30
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose methotrexate (0.5 g/m2) (MHD-MTX) without cranial radiotherapy (CRT) in low-risk patients
Number of subjects: 4000
Study 9743952 — intervention group
Group type: COMPARATOR
Intervention: MHD-MTX without CRT in intermediate-risk patients
Number of subjects: 4000
Study 9743952 — intervention group
Group type: COMPARATOR
Intervention: MHD-MTX with 12 Gy or 18 Gy of preventive CRT in intermediate-risk patients
Number of subjects: 4000
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) with reduced CRT (12 Gy for IR, 18 Gy for MR, and 18 Gy for HR)
Number of subjects: 4000
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive preventive CRT (12 Gy for all medium and high-risk patients) in trial ALL-BFM 90
Number of subjects: 4000
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CRT (12 Gy) and HD-MTX in T-cell ALL patients
Number of subjects: 4000
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systemic and intrathecal chemotherapy without CRT in low-risk ALL patients
Number of subjects: 4000
Study 9743952 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS-directed systemic and intrathecal chemotherapy combined with 12 Gy CRT in trial ALL-BFM 90
Number of subjects: 4000
Study 8053591 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.6, 1.0, and 1.4 MAC)
Number of subjects: 50
Study 8053591 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (1.0 MAC) during surgical incision
Number of subjects: 50
Study 8053591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen (0.3, 0.45, and 0.6 MAC)
Number of subjects: 50
Study 8053591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anesthetic concentrations (associated with response to verbal command)
Number of subjects: 50
Study 3183370 — intervention group
Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once a day
Number of subjects: 12
Study 3183370 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31530044 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Related Productivity Questionnaire (HRPQ)
Number of subjects: 1686
Study 31530044 — intervention group
Group type: COMPARATOR
Intervention: EM-I trial
Number of subjects: 1686
Study 31530044 — intervention group
Group type: COMPARATOR
Intervention: EM-II trial
Number of subjects: 1686
Study 31009067 — intervention group
Group type: EXPERIMENTAL
Intervention: Granger Mediation Analysis (GMA) framework applied to fMRI data
Number of subjects: 0
Study 31009067 — intervention group
Group type: COMPARATOR
Intervention: Existing approaches
Number of subjects: 0
Study 28662647 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 54
Study 28662647 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 54
Study 25125353 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge ECG Holter monitoring
Number of subjects: 133
Study 23696221 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Rotadisk/Diskhaler
Number of subjects: 18
Study 23696221 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Rotacap/Rotahaler
Number of subjects: 18
Study 23696221 — intervention group
Group type: COMPARATOR
Intervention: Placebo via Rotacap/Rotahaler
Number of subjects: 18
Study 22067185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release 300 mg
Number of subjects: 189
Study 22067185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 19339560 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 100
Study 19339560 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 100
Study 19339560 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene (men)
Number of subjects: 100
Study 19339560 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (men)
Number of subjects: 100
Study 19339560 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (women)
Number of subjects: 100
Study 17010497 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional refresher classes at intervals of 7 and 12 months
Number of subjects: 0
Study 17010497 — intervention group
Group type: COMPARATOR
Intervention: One additional refresher class after 12 months
Number of subjects: 0
Study 15526703 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative clinical rotation
Number of subjects: 0
Study 15526703 — intervention group
Group type: COMPARATOR
Intervention: Other clinical rotations
Number of subjects: 0
Study 11209120 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser (Silktouch mode, 260 handpiece, fluence 15 J/cm(2), 10 mm(2))
Number of subjects: 9
Study 11209120 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgical device (ESD, 125 V = setting 4, 5 mm handpiece)
Number of subjects: 9
Study 11209120 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 9
Study 11209120 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgical device (ESD)
Number of subjects: 9
Study 9307630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive lens (811E, Pharmacia; power add +4.0 D)
Number of subjects: 80
Study 9307630 — intervention group
Group type: COMPARATOR
Intervention: Refractive lens (PA154N, Allergan; power add +3.5 D)
Number of subjects: 80
Study 8350885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vest CPR (60 inflations per minute)
Number of subjects: 49
Study 8350885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vest CPR
Number of subjects: 49
Study 8350885 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 49
Study 3087656 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg orally per day
Number of subjects: 74
Study 3087656 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 100 micrograms in each nostril twice daily
Number of subjects: 74
Study 3087656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 74
Study 3087656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral astemizole
Number of subjects: 74
Study 29662293 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 607
Study 29662293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 607
Study 29662293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 607
Study 28805934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermo-cosmetics in combination with topical acne treatment (adapalene 0.1% gel)
Number of subjects: 0
Study 28805934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermo-cosmetic products
Number of subjects: 0
Study 26205644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 105
Study 26205644 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 105
Study 26205644 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of sevoflurane and propofol (group C)
Number of subjects: 105
Study 24001251 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MARS intervention (sexual-risk-reduction intervention including screening and treatment for chlamydia and gonorrhea)
Number of subjects: 206
Study 24001251 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MARS intervention (including viral STIs in the economic analysis)
Number of subjects: 206
Study 24001251 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MARS intervention (contingent valuation model)
Number of subjects: 206
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin concentration ≥2 mg/L at day 29
Number of subjects: 382
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin concentration <2 mg/L at day 29
Number of subjects: 382
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week treatment group with ribavirin concentration ≥2 mg/L
Number of subjects: 382
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week treatment group with ribavirin concentration <2 mg/L
Number of subjects: 382
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week treatment group with ribavirin concentration ≥2 mg/L
Number of subjects: 382
Study 20384961 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week treatment group with ribavirin concentration <2 mg/L
Number of subjects: 382
Study 19055294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanometer acupoint mounting method at 4 Jiaji points and other acupoints (Shenshu, Shangliao, Ciliao, Yang-lingquan, Xuanzhong)
Number of subjects: 60
Study 19055294 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide sticking tablets at the same acupoints
Number of subjects: 60
Study 16836477 — intervention group
Group type: EXPERIMENTAL
Intervention: FRIENDS Program
Number of subjects: 0
Study 16836477 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 12971122 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 0
Study 12971122 — intervention group
Group type: COMPARATOR
Intervention: Standard Supportive Treatment
Number of subjects: 0
Study 11105976 — intervention group
Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 0
Study 11105976 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphs
Number of subjects: 0